UroGen Pharma Ltd [URGN] stock is trading at $11.26, up 14.08%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The URGN shares have gain 16.56% over the last week, with a monthly amount drifted -1.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on April 16, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $23. On August 22, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $40 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $10 on February 08, 2023. Berenberg initiated its recommendation with a Buy and recommended $20 as its price target on April 27, 2022. H.C. Wainwright reiterated a Buy rating for this stock on April 16, 2020, and upped its price target to $57. In a note dated April 13, 2020, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $75 to $53.
UroGen Pharma Ltd [URGN] stock has fluctuated between $8.94 and $20.70 over the past year. Currently, Wall Street analysts expect the stock to reach $38.6 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $11.26 at the most recent close of the market. An investor can expect a potential return of 242.81% based on the average URGN price forecast.
Analyzing the URGN fundamentals
UroGen Pharma Ltd [NASDAQ:URGN] reported sales of 90.40M for the trailing twelve months, which represents a growth of 4.40%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.07%, Pretax Profit Margin comes in at -1.37%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -73.64 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-14.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.31 points at the first support level, and at 9.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.94, and for the 2nd resistance point, it is at 12.63.
Ratios To Look Out For
For context, UroGen Pharma Ltd’s Current Ratio is 6.01. Further, the Quick Ratio stands at 5.81, while the Cash Ratio is 3.74. Considering the valuation of this stock, the price to sales ratio is 5.74.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jan 31 ’25 when 4551.0 shares were sold. General Counsel, Smith Jason Drew completed a deal on Jan 31 ’25 to sell 7379.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 859.0 shares on Sep 09 ’24.
